Expected Increase In Research And Development

By Arthur Pinkasovitch | November 08, 2010 AAA

Research and development (R&D) plays an integral role in the success of pharmaceutical firms. According to a study conducted by Booz & Co, the healthcare industry had R&D expenditures of over $111 billion in 2009. Based on evidence provided in the report, of the 10 most research-intensive firms in the world, six are in the healthcare industry.

IN PICTURES: 5 Tips To Reading The Balance Sheet

The Tech Factor
Not surprisingly, tech-based firms such as Nokia (NYSE:NOK) and IBM (NYSE:IBM) cumulatively devoted the most resources to research and development, while the auto industry, which is pushing to rebrand its image to one of a more environmentally friendly business, came in third. Computing/electronics and autos had 2009 R&D expenditures of $146.7 and $85.2 billion respectively.

R&D in Healthcare
After analyzing R&D spending of the world's 1,000 top innovation-driven companies, Booz & Co. revealed that 2009 spending decreased by an average 3.5%. Although most of the declines were attributed to the auto industry, many American healthcare firms saw cutbacks as well.

Pfizer (NYSE:PFE) and Johnson & Johnson (NYSE:JNJ), which ranked in the five and seven spots on the list, saw year-over-year outlays decrease by 2.6% and 7.8% respectively.

Expiring Patents
However, with improving economic conditions, major pharmaceuticals are forced to renew their focus on R&D spending. As numerous major drugs such as Pfizer's Lipitor and GlaxoSmithKline's (NYSE:GSK) Advair lose their patents, generic drug makers will enter the market and begin to mass produce these medications. The best-selling cholesterol drug, Lipitor, contributed $8.1 billion to Pfizer's top line as of the first nine months of 2010. In fact, Lipitor sales contribute approximate 16.1% to Pfizer's total year to date revenue. Xalatan, another drug with an expiring patent in 2011 produced third-quarter sales of $416 million.

Competition
Israel's generic pharmaceutical giant, Teva (Nasdaq:TEVA), is set to capitalize on the growing list of patents set to expire in upcoming years. A major advantage for generic drug manufacturers is that they can allocate fewer resources to R&D. For example, Teva's nine-month R&D-to-sales ratio sits at 5.7%, compared to Pfizer's 13.1%.

In its latest quarter, Teva's North American sales increased by 22%, largely driven by a generic version of Pfizer's antidepressant, Effexor.

The major drug companies have two primary alternatives to maintain revenue growth: boost R&D spending and/or acquire competitors with drugs in the pipeline, which can replace the sales lost to generic brands. The major drug companies have been utilizing both approaches.

Merck (NYSE:MRK) increased its third-quarter research and development expense by 77%, spending $2.3 billion compared to $1.3 billion in 2009. Likewise, Pfizer's R&D spending surged from $1.63 billion to $2.19 billion. Furthermore, both of these corporations have been involved in large acquisitions with Merck purchasing Millipore for $7 billion. Pfizer is acquiring Wyeth for $68 billion.

The Bottom Line
Research and development spending is a crucial component of the pharmaceutical industry, as drug companies cannot rely on previously-developed technology to drive profits indefinitely. With many major patents expiring in 2011, companies will be forced to find alternative revenue streams. (Investors take note: companies that cut research and development are in danger of saving today but losing big tomorrow. Check out Buying Into Corporate Research & Development.)

Use the Investopedia Stock Simulator to trade the stocks mentioned in this stock analysis, risk free!

You May Also Like

Related Analysis
  1. Is Natural Gas About to Tank?
    Chart Advisor

    Is Natural Gas About to Tank?

  2. This ETF Offers Easy Access To Big Pharma
    Chart Advisor

    This ETF Offers Easy Access To Big Pharma

  3. Pharma Industry Outlook: M&A, Licensing Abound - Industry Outlook
    Stock Analysis

    Pharma Industry Outlook: M&A, Licensing Abound - Industry Outlook

  4. Is It A Breakout? See The Point-And-Figure Chart
    Chart Advisor

    Is It A Breakout? See The Point-And-Figure Chart

  5. These Stocks Offer Range-Trading Opportunities
    Chart Advisor

    These Stocks Offer Range-Trading Opportunities

Trading Center